These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

402 related items for PubMed ID: 27575713

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Randomized, controlled trial of carvedilol versus nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding.
    Lo GH, Chen WC, Wang HM, Yu HC.
    J Gastroenterol Hepatol; 2012 Nov; 27(11):1681-7. PubMed ID: 22849337
    [Abstract] [Full Text] [Related]

  • 24. Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis.
    Lin HC, Yang YY, Hou MC, Huang YT, Lee FY, Lee SD.
    Am J Gastroenterol; 2004 Oct; 99(10):1953-8. PubMed ID: 15447755
    [Abstract] [Full Text] [Related]

  • 25. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
    Villanueva C, Albillos A, Genescà J, Garcia-Pagan JC, Calleja JL, Aracil C, Bañares R, Morillas RM, Poca M, Peñas B, Augustin S, Abraldes JG, Alvarado E, Torres F, Bosch J.
    Lancet; 2019 Apr 20; 393(10181):1597-1608. PubMed ID: 30910320
    [Abstract] [Full Text] [Related]

  • 26. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.
    Ripoll C, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R, Escorsell A, Garcia-Pagan JC, Makuch R, Patch D, Matloff DS, Bosch J, Portal Hypertension Collaborative Group.
    Gastroenterology; 2007 Aug 20; 133(2):481-8. PubMed ID: 17681169
    [Abstract] [Full Text] [Related]

  • 27. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed.
    Tripathi D, Ferguson JW, Kochar N, Leithead JA, Therapondos G, McAvoy NC, Stanley AJ, Forrest EH, Hislop WS, Mills PR, Hayes PC.
    Hepatology; 2009 Sep 20; 50(3):825-33. PubMed ID: 19610055
    [Abstract] [Full Text] [Related]

  • 28. Comparative randomized study on efficacy of losartan versus propranolol in lowering portal pressure in decompensated chronic liver disease.
    Agasti AK, Mahajan AU, Phadke AY, Nathani PJ, Sawant P.
    J Dig Dis; 2013 May 20; 14(5):266-71. PubMed ID: 23280243
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis.
    Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodés J, Bosch J.
    Hepatology; 2003 Apr 20; 37(4):902-8. PubMed ID: 12668985
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Hemodynamic Response to Carvedilol is Maintained for Long Periods and Leads to Better Clinical Outcome in Cirrhosis: A Prospective Study.
    Kirnake V, Arora A, Gupta V, Sharma P, Singla V, Bansal N, Goyal M, Chawlani R, Kumar A.
    J Clin Exp Hepatol; 2016 Sep 20; 6(3):175-185. PubMed ID: 27746613
    [Abstract] [Full Text] [Related]

  • 34. Damping index of Doppler hepatic vein waveform to assess the severity of portal hypertension and response to propranolol in liver cirrhosis: a prospective nonrandomized study.
    Kim MY, Baik SK, Park DH, Lim DW, Kim JW, Kim HS, Kwon SO, Kim YJ, Chang SJ, Lee SS.
    Liver Int; 2007 Oct 20; 27(8):1103-10. PubMed ID: 17845539
    [Abstract] [Full Text] [Related]

  • 35. Carvedilol in the treatment of portal hypertension.
    Al-Ghamdi H.
    Saudi J Gastroenterol; 2011 Oct 20; 17(2):155-8. PubMed ID: 21372358
    [Abstract] [Full Text] [Related]

  • 36. 5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial.
    Vukotic R, Di Donato R, Roncarati G, Simoni P, Renzulli M, Gitto S, Schepis F, Villa E, Berzigotti A, Bosch J, Andreone P.
    J Hepatol; 2023 Oct 20; 79(4):977-988. PubMed ID: 37482222
    [Abstract] [Full Text] [Related]

  • 37. Carvedilol to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by liver stiffness: study protocol for a randomied, double-blind, placebo-controlled, multicentre trial in China.
    Liu C, Zhang L, Zhang S, Li X, Wong YJ, Liang X, Wang Y, Wu X, Gou W, Lv J, Hu S, Fu J, Huang J, Ge G, Huang M, Wang F, Zhang Q, Ren T, Meng Z, Ding D, Zhuoga B, Zhuoga C, Fan J, Dang D, Miao L, Song Z, Xiao X, Wu H, Jiang K, Liu T, Gao Y, Ma L, Fang T, Wang Y, Zhang Q, Zhu D, Ji D, Cao Z, Zeng QL, Li J, Chen P, Wei Y, Tong Z, Hong Z, Liang X, Li Y, Nan Y, Qi X.
    BMJ Open; 2024 Jul 11; 14(7):e081623. PubMed ID: 38991669
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study.
    Bishnu S, Ahammed SM, Sarkar A, Hembram J, Chatterjee S, Das K, Dhali GK, Chowdhury A, Das K.
    Eur J Gastroenterol Hepatol; 2018 Jan 11; 30(1):54-59. PubMed ID: 29099421
    [Abstract] [Full Text] [Related]

  • 40. Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
    Bhardwaj A, Kedarisetty CK, Vashishtha C, Bhadoria AS, Jindal A, Kumar G, Choudhary A, Shasthry SM, Maiwall R, Kumar M, Bhatia V, Sarin SK.
    Gut; 2017 Oct 11; 66(10):1838-1843. PubMed ID: 27298379
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.